Drug Interaction Report

Alogliptin and Lanreotide Acetate: Interaction Details

A pharmacist-reviewed analysis of the Alogliptin and Lanreotide Acetate interaction: the documented clinical effects, severity rating, onset, mechanism, and management considerations, with cited references throughout.

AI-assisted, pharmacist-reviewed · Source data updated Aug 8, 2026 · Sources: FDA labeling, DDInter 2.0, cited literature

Alogliptin

Nesina Nesina®
+

Lanreotide Acetate

No brand names on record
Dr. Brian Staiger, PharmD, BCPS
Medically reviewed by
Dr. Brian Staiger, PharmD, BCPS
Updated Aug 8, 2026
Editorial policy · Data sources
LinkedIn
Interaction severity
Major
Potentially serious — often needs a change or close monitoring.
How we grade severity & evidence

Severity levels

  • Contraindicated: These should generally not be used together.
  • Major: Potentially serious — often needs a change or close monitoring.
  • Moderate: Can be significant — usually manageable with monitoring.
  • Minor: Usually limited clinical impact.

Evidence grades

  • Established: Well documented — supported by controlled studies or strong clinical data.
  • Probable: Good supporting evidence, though not definitively proven.
  • Suspected: Some evidence suggests this interaction, but it is not well established.
  • Possible: Limited or conflicting evidence; the interaction may occur.
  • Theoretical: Predicted from the drugs' pharmacology; not yet confirmed in people.

Ratings come from the documented interaction literature and are reviewed by a pharmacist. They describe the documented risk of the combination, not what will necessarily happen to you — your dose, timing, and health picture all matter.

Of 129 documented Alogliptin interactions, 81 are rated major — including this one.
Worried about symptoms right now? Contact your pharmacist or prescriber, or call Poison Control at 1-800-222-1222 (US). Call 911 for an emergency.
Onset
unspecified
Evidence
theoretical
Severity
Major

What happens

An increased risk of hypoglycemia and impaired glucose regulation

Interaction Deep Dive

Somatostatin analogs inhibit the secretion of insulin and glucagon3. Severe increases in blood glucose levels may occur. Optimize antidiabetic treatment in patients with poorly-controlled diabetes prior to starting the somatostatin analog 4. Dose adjustment of the antidiabetic agent and increased frequency of glucose monitoring may be necessary 125.

Why it happens (mechanism)

Altered glucose metabolism

Common questions

Can I take Alogliptin and Lanreotide Acetate together?

An increased risk of hypoglycemia and impaired glucose regulation Always confirm with your pharmacist or prescriber before making any change.

How serious is the Alogliptin and Lanreotide Acetate interaction?

It is rated major. Potentially serious — often needs a change or close monitoring.

How quickly could this interaction happen?

The documented onset is "unspecified". The timing of this interaction is not well characterized.

How strong is the evidence for this interaction?

The evidence is graded "theoretical". Predicted from the drugs' pharmacology; not yet confirmed in people.

Questions for your pharmacist

  • Does my dose of Alogliptin or Lanreotide Acetate need adjusting while I take them together?
  • What symptoms should prompt me to call you or my prescriber right away?
  • Does the timing of my doses matter for this combination?
  • Is there a safer alternative to one of these medications for me?

References (5)

  1. Product Information: TOUJEO(R) subcutaneous injection, insulin glargine subcutaneous injection. sanofi-aventis (per manufacturer), Bridgewater, NJ, 2015. DailyMed
  2. Product Information: Tresiba subcutaneous injection solution, insulin degludec subcutaneous injection solution. Novo Nordisk A/S (per EMA), Bagsvaerd, Denmark, 2013. DailyMed
  3. Product Information: Sandostatin(R) LAR Depot intramuscular injection suspension, octreotide acetate intramuscular injection suspension. Novartis Pharmaceuticals Corporation (per FDA), East Hanover, NJ, 2014.
  4. Product Information: SIGNIFOR(R) LAR intramuscular injection suspension, pasireotide intramuscular injection suspension. Novartis Pharmaceuticals Corporation (per FDA), East Hanover, NJ, 2014.
  5. Product Information: ADMELOG(R) subcutaneous, intravenous injection, insulin lispro subcutaneous, intravenous injection. sanofi-aventis US LLC (per DailyMed), Bridgewater, NJ, 2023. DailyMed
Was this write-up helpful?
Alogliptin

Keep reading about Alogliptin

All Alogliptin interactions (129) Alogliptin drug information
Also serious with: Colchicine Insulin Detemir (Rdna Origin) Injection Abiraterone Abiraterone Acetate
Lanreotide Acetate

Keep reading about Lanreotide Acetate

All Lanreotide Acetate interactions (19)
Also serious with: Nateglinide Lixisenatide Injection Dapagliflozin Miglitol
Beyond drug–drug

These medications also interact with supplements

Prescription drugs aren't the whole picture — herbal and dietary supplements can interact with them too. From the evidence-graded Natural Medicines database:

Alogliptin + Activated Charcoal Beer Grapefruit Siberian Cocklebur St. John's Wort Wine Acacia Rigidula Acai + 348 more

major · moderate · minor — check everything you take with our drug–supplement interaction checker.

Check another combination

Our instant two-drug interaction checker is almost here.

Coming soon

The instant two-drug checker is on its way.

In the meantime, browse the directory below to look up any drug and see its documented interactions.

Still have questions about this combination?

Every question gets a real answer from a licensed pharmacist — free, and usually within a day.

Ask the pharmacist
This information is for education, not a substitute for professional medical advice. Do not start, stop, or change any medication without talking to your pharmacist or prescriber.